公开(公告)号：WO9502603A2

公开(公告)日：1995-01-26

申请号：PCT/EP9402059

申请日：1994-06-24

Applicant: PHARMACIA SPA ,  ALPEGIANI MARCO ,  BISSOLINO PIERLUIGI ,  PERRONE ETTORE ,  PESENTI ENRICO

Inventor： ALPEGIANI MARCO ,  BISSOLINO PIERLUIGI ,  PERRONE ETTORE ,  PESENTI ENRICO

IPC: A61K31/545 ,  C07D501/00

CPC classification number: C07D501/00 ,  A61K31/545

Abstract: The present invention relates to the use of known cephem derivatives of formula (I), wherein n is zero, one or two; R is hydrogen or an organic radical, R represents halo or an organic radical or R and R taken together with the C-2 carbon atom of the cephem nucleus constitute a carbocyclic or heterocyclic group; R represents R as defined above or an organic radical, R is either R or an organic group, R is either R as defined above or halo or C1-C6 alkoxy, C1-C6 alkylthio or C1-C6 acylamino; R is R as defined above or an organic group, or pharmaceutically acceptable salt thereof.

Abstract translation: 本发明涉及式（I）的已知头孢烯衍生物的用途，其中n为0,1或2; R 1是氢或有机基团，R 2表示卤素或有机基团，或者R 1和R 2与头孢烯核的C-2碳原子一起构成碳环或杂环基 ; R 3表示如上所定义的R 2或有机基团，R 4为R 1或有机基团，R 5为如上定义的R 1或卤素或C 1 -C 6烷基， C6烷氧基，C1-C6烷硫基或C1-C6酰氨基; R 6是如上定义的R 2或有机基团或其药学上可接受的盐。

公开(公告)号：WO9502603A3

公开(公告)日：1995-03-09

申请号：PCT/EP9402059

申请日：1994-06-24

Applicant: PHARMACIA SPA ,  ALPEGIANI MARCO ,  BISSOLINO PIERLUIGI ,  PERRONE ETTORE ,  PESENTI ENRICO

Inventor： ALPEGIANI MARCO ,  BISSOLINO PIERLUIGI ,  PERRONE ETTORE ,  PESENTI ENRICO

IPC: A61K31/545 ,  C07D501/00

CPC classification number: C07D501/00 ,  A61K31/545

Abstract: The present invention relates to the use of known cephem derivatives of formula (I), wherein n is zero, one or two; R1 is hydrogen or an organic radical, R2 represents halo or an organic radical or R?1 and R2¿ taken together with the C-2 carbon atom of the cephem nucleus constitute a carbocyclic or heterocyclic group; R3 represents R2 as defined above or an organic radical, R4 is either R1 or an organic group, R5 is either R1 as defined above or halo or C¿1?-C6 alkoxy, C1-C6 alkylthio or C1-C6 acylamino; R?6 is R2¿ as defined above or an organic group, or pharmaceutically acceptable salt thereof.

Abstract translation: PCT No.PCP / EP94 / 02059 Sec。 371日期：1995年3月8日 102（e）1995年3月8日PCT PCT 1994年6月24日PCT公布。 公开号WO95 / 02603 日本1995年1月26日本发明涉及已知的头孢烯衍生物，其具有下式：其中R 1表示卤素或有机基团，或者R 1和R 2与C-2碳原子一起 头孢烯核构成碳环或杂环基; R3表示如上所定义的R 2或有机基团，R 4为R 1或有机基团，R 5为如上定义的R 1或卤素或C 1 -C 6烷氧基，C 1 -C 6烷硫基或C 1 -C 6酰氨基; R6是如上定义的R2或有机基团，或其药学上可接受的盐。

公开(公告)号：WO9516693A3

公开(公告)日：1995-07-20

申请号：PCT/EP9403893

申请日：1994-11-24

Applicant: PHARMACIA SPA

Inventor： BARGIOTTI ALBERTO ,  CARUSO MICHELE ,  GRANDI MARIA ,  RIPAMONTI MARINA ,  SUARATO ANTONINO

IPC: A61K31/70 ,  A61K31/7028 ,  A61K31/7034 ,  A61K31/704 ,  A61P35/00 ,  C07H15/252

CPC classification number: C07H15/252

Abstract: Compounds which are anthracycline glycosides of general formula (1) or (2), wherein R1 is hydrogen or a methoxy group; one of R2 and R3 is hydrogen and the other is a sulfonyl residue R4SO2O- in which R4 is a linear or branched C1-C8 alkyl, or an aryl which is unsubstituted or substituted with at least one linear or branched C1-C6 alkyl or a C1-C6 alkoxy group, a halogen atom, an amino or a nitro group; or a pharmaceutically acceptable salt thereof are active as antitumor agents. A process for the preparation thereof and pharmaceutical compositions containing such a compound are also disclosed.

公开(公告)号：WO9523806A3

公开(公告)日：1995-09-28

申请号：PCT/EP9500444

申请日：1995-02-08

Applicant: PHARMACIA SPA ,  MONGELLI NICOLA ,  GRUGNOLA ANGELO ,  LOMBARDI BORGIA ANDREA ,  PESENTI ENRICO

Inventor： MONGELLI NICOLA ,  GRUGNOLA ANGELO ,  LOMBARDI BORGIA ANDREA ,  PESENTI ENRICO

IPC: A61K31/675 ,  A61P9/00 ,  A61P29/00 ,  A61P31/12 ,  A61P31/18 ,  A61P33/02 ,  A61P37/06 ,  C07F9/38 ,  C07F9/40 ,  C07F9/572

CPC classification number: C07F9/5722

Abstract: PCT No. PCT/EP95/00444 Sec. 371 Date Oct. 30, 1995 Sec. 102(e) Date Oct. 30, 1995 PCT Filed Feb. 8, 1995 PCT Pub. No. WO95/23806 PCT Pub. Date Sep. 8, 1995Subject of the present invention are new ureido derivatives of naphthalenephosphonic acids having the following formula (I) (I) wherein each of m and n, which are the same, is an integer of 1 to 4; each of p and q, which are the same, is an integer of 1 to 3; and each of the R groups, which are the same, is a free or esterified phosphonic acid group; and the pharmaceutically acceptable salts thereof.

公开(公告)号：WO9516695A3

公开(公告)日：1995-07-13

申请号：PCT/EP9403840

申请日：1994-11-21

Applicant: PHARMACIA SPA

Inventor： BARGIOTTI ALBERTO ,  CARUSO MICHELE ,  GRANDI MARIA ,  RIPAMONTI MARINA ,  SUARATO ANTONIO

IPC: A61K31/70 ,  A61K31/7028 ,  A61K31/7034 ,  A61K31/704 ,  A61P35/00 ,  C07H15/252 ,  C07H17/02

CPC classification number: C07H15/252 ,  C07H17/02

Abstract: Anthracycline glycosides of general formula 1 and 2: 1 2 wherein R1 is hydrogen or a methoxy group; R2 is hydrogen, a hydroxy group or represents an acyloxy residue of formula 3 -O-COR5 wherein R5 is a linear or branched C1-C8 alkyl, an aryl group or a heterocyclic mono or bicyclic ring, each of which may be unsubstituted or substituted with (a) an amino group NR6R7 in which R6 and R7 are independently hydrogen or C1-C4 alkyl or (b) a carboxy group; R3 and R4 both represent hydrogen or one of R3 and R4 is hydrogen and the other is hydroxy group or a group of formula -OSO2R8 in which R8 may be a linear or branched alkyl group containing from 1 to 6 carbon atoms or an aryl group unsubstituted or substituted by 1 to 3 substituents each of which may independently be a linear or branched alkyl or alkoxy group of from 1 to 6 carbon atoms, a halogen atom or a nitro group; and pharmaceutically acceptable salts thereof; are active as antitumor agents.